MedTrace Logo

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

NCT00040404 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 806

Last updated 2012-05-10

No results posted yet for this study

Summary

The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

CEP-1347 10mg

CEP-1347 10mg, a K252a derivative, retains neuroprotective properties

DRUG

CEP1347 25mg

CEP1347 25mg, a K252a derivative, retains neuroprotective properties

DRUG

CEP-1347 50mg

CEP-1347 50mg, a K252a derivative, retains neuroprotective properties

OTHER

Placebo Comparator

Placebo capsules matching the CEP-1347 capsules

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • The Parkinson Study Group

    collaborator NETWORK

  • Cephalon

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2005-08-31
Completion
2005-08-31

Countries

  • United States
  • Canada
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00040404 on ClinicalTrials.gov